(S029) Patient-Reported Voice and Speech Outcomes and Their Clinical and Dosimetric Predictors After Chemo-IMRT of Oropharyngeal Cancer: A Prospective Longitudinal Study

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

Although adverse sequelae of chemoradiation (CRT) for head and neck cancer (HNC) have been extensively detailed in recent years, the effects of CRT on voice and speech quality remain poorly characterized. We investigated changes in patient-reported voice and speech quality (VSQ) after CRT in two prospective studies of organ-sparing CRT for locally advanced oropharyngeal cancer (OPC).

Jeffrey M. Vainshtein, MD, Kent A. Griffith, MS, Felix Y. Feng, MD, Karen A. Vineberg, MS, Douglas B. Chepeha, MD, MSPH, Avraham Eisbruch, MD; University of Michigan

Purpose and Objectives: Although adverse sequelae of chemoradiation (CRT) for head and neck cancer (HNC) have been extensively detailed in recent years, the effects of CRT on voice and speech quality remain poorly characterized. We investigated changes in patient-reported voice and speech quality (VSQ) after CRT in two prospective studies of organ-sparing CRT for locally advanced oropharyngeal cancer (OPC).

Materials and Methods: A total of 91 patients with stage III/IV OPC treated at our institution in two prospective studies of definitive CRT from 2003–2011 were included. All received whole-field neck intensity-modulated radiation therapy (IMRT) intended to minimize dose to the pharyngeal constrictors, salivary glands, oral cavity (OC), glottic larynx (GL), supraglottic larynx, and esophagus. Patient-reported VSQ (PRVSQ) was assessed by the Communication Domain of the Head and Neck Quality of Life (HNQOL-C) questionnaire and the speech question of the University of Washington QOL (UWQOL-S) questionnaire at pretreatment and 3, 6, 12, 18, and 24 months after CRT. Factors associated with worsening PRVSQ (defined as a decrease in HNQOL-C or UWQOL-S from baseline) were assessed.

Results: PRVSQ decreased maximally at 1 month, with 68% and 41% of patients reporting worsening HNQOL-C and UWQOL-S scores compared with baseline, and improved thereafter, with recovery of mean population HNQOL-C and UWQOL-S scores to baseline by 12 and 18 months, respectively. At 12 months, however, 33% and 28% of patients continued to report lower HNQOL-C and UWQOL-S scores compared with pretreatment, respectively. In contrast to patient-reported effects, observer-rated larynx toxicity was rare, with only grade 1 toxicity reported by 5% at 6 months and 0% at 12 months. Of patients with mean GL dose of < 20 Gy, > 20–30 Gy, > 30–40 Gy, > 40–50 Gy, and > 50 Gy, 25%, 33%, 59%, 50%, and 64% reported worse HNQOL-C scores at 6 months compared with pretreatment, which persisted at 12 months in 10%, 32%, 25%, 30%, and 63% of patients, respectively (χ2 for trend: P = .02 at 6 months; P = .011 at 12 months). Results using a worsening UWQOL-S score endpoint were similar. Mean GL dose, mean OC dose, N2/3 stage, and shorter time since RT completion were associated with worsening HNQOL-S (P < .05) on univariate analysis. On multivariate analysis, mean GL dose remained independently predictive for worsening HNQOL-S after CRT (odds ratio [OR] = 1.08 per Gy; P < .01).

Conclusions: In the largest prospective study to assess voice and speech outcomes after CRT for OPC, worsening VSQ was frequently reported by patients, underrecognized by clinicians, and independently associated with dose to the GL. These findings support limiting mean GL dose to < 20 Gy during whole-neck IMRT for HNC when the larynx is not a target.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content